Endothelial dysfunction: Methods of assessment & implications for cardiovascular diseases

Current Pharmaceutical Design

Volumn 16, Issue 31, 2010, Pages 3442-3454

  Butt, Mehmood ^a   Dwivedi, Girish ^a   Blann, Andrew ^a   Khair, Omer ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular prognosis; Endothelial dysfunction; Endothelium

Indexed keywords

ANTIDIABETIC AGENT; ARGININE; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; IMAGING SYSTEM; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STEM CELL; VASCULAR ENDOTHELIUM; VASODILATATION;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, CARDIOVASCULAR; PROGNOSIS; RISK FACTORS;

EID: 78649947965     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563383     Document Type: Article

References (175)

1. Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes D, Lerman A. Attenuated coronary flow reserve and vascular remodel ing in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol 2000; 35: 1654-60.
2. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-16.
3. Neri S, Bruno CM, Leotta C, D'Amico RA, Pennisi G, Ierna D. Early endothelial alterations in non-insulin-dependent diabetes mel-litus. Int J Clin Lab Res 1998; 28: 100-3.
4. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hy-percholesterolemic patients. Circulation 1993; 88: 2541-7.
5. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994; 90: 5-11.
6. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8
7. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
8. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothe-lial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
9. Hwa C, Sebastian A, Aird WC. Endothelial biomedicine: its status as an interdisciplinary field, its progress as a basic science, and its translational bench-to-bedside gap. Endothelium 2005; 12: 139-51.
10. Miura H, Watchel RE, Liu Y, et al. Flow-induced dilation of human coronary arterioles: important role of Ca (2+)-activated K(+) channels. Circulation 2001; 103: 1992-8.
11. Ohno M, Gibbons GH, Dzau VJ, Cooke JP. Shear stress elevates endothelial cGMP. Role of a potassium channel and G protein cou pling. Circulation 1993; 88: 193-7.
12. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Eng J Med 1993; 329: 2002-12.
13. Jones CJH, Kuo L, Davis MJ, deFily DV, Chillian WM. Role of nitric oxide in coronary microvascular responses to adenosine and increased metabolic demand. Circulation 1996; 91: 1807-13.
14. Cooke JP, Tsao PS: Go with the flow. Circulation 2001; 103: 2773-5.
15. Choi EY. Inhibition of leukocyte adhesion by developmental endo-thelial locus-1 (del-1). Immune Network 2009; 9: 153-7.
16. Choi EY, Chavakis E, Czabanka MA, et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 2008; 322: 1101-4.
17. Crea F, Biasucci LM, Buffon A, et al. Role of inflammation in the pathogenesis of unstable coronary artery disease. Am J Cardiol 1997; 80(5A): 10E-E16.
18. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035-40.
19. Sinzinger H, Zidek T, Fitscha P, O'Grady J, Wagner O, Kaliman J. Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo. Prostaglandins 1987; 33: 915-8.
20. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstric-tion induced by acetylcholine in atherosclerosis coronary arteries. N Engl J Med 1986; 315: 1046-51.
21. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
22. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34; 631-8.
23. Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 2001; 37: 1523-8.
24. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
25. Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 2001; 157: 369-73.
26. Corretti MC, Anderson TJ, Benjamin EJ, et al. International brachial artery reactivity task force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002; 39: 257-65.
27. Rosas EA, González AM, Castillo LG, et al. Endothelial function assessment by positron emission tomography in patients with hypercholesterolemia. Arch Cardiol Mex 2008; 78: 139-47.
28. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994; 330: 1782-8.
29. Pitkänen OP, Raitakari OT, Niinikoski H, et al. Coronary flow reserve is impaired in young men with familial hypercholes-terolemia. J Am Coll Cardiol 1996; 28: 1705-11.
30. Laine H, Raitakari OT, Niinikoski H, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998; 32: 147-53.
31. Hirsch A, Nijveldt R, Haeck JD, et al. Relation between the assessment of microvascular injury by cardiovascular magnetic resonance and coronary Doppler flow velocity measurements in patients with acute anterior wall myocardial infarction. J Am Coll Cardiol 2008; 51: 2230-8.
32. Wöhrle J, Nusser T, Merkle N, et al. Myocardial perfusion reserve in cardiovascular magnetic resonance: Correlation to coronary microvascular dysfunction. J Cardiovasc Magn Reson 2006; 8: 781-7.
33. Dwivedi G, Janardhanan R, Hayat SA, Swinburn JM, Senior R. Prognostic value of myocardial viability detected by myocardial contrast echocardiography early after acute myocardial infarction. J Am Coll Cardiol 2007; 50: 327-34.
34. Di Bello V, Giorgi D, Pedrinelli R, et al. Early impairment of myo-cardial blood flow reserve in men with essential hypertension: a quantitative myocardial contrast echocardiography study. J Am Soc Echocardiogr 2004; 17: 1037-43.
35. Jayaweera AR, Edwards N, Glasheen WP, Villanueva FS, Abbott RD, Kaul S. In vivo myocardial kinetics of air-filled albumin micro bubbles during myocardial contrast echocardiography: comparison with radio-labeled red blood cells. Circ Res 1994; 74: 1157-65.
36. Keller MW, Segal SS, Kaul S, Duling B. The behavior of sonicated albumin microbubbles within the microcirculation: a basis for their use during myocardial contrast echocardiography. Circ Res 1989; 65: 458-67.
37. Wei K, Jayaweera AR, Firoozan S. Quantification of MBF flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97: 473-83.
38. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-7.
39. Yoshida M, Tomiyama H, Yamada J, et al. Relationship of insulin resistance to macro- and microvasculature reactivity in hypertension. Am J Hypertens 2010 Jan 28. [Epub ahead of print].
40. Yaqoob M, Patrick AW, McClelland P, et al. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus. Clin Sci (Lond) 1993; 85: 557-62.
41. Huvers FC, De Leeuw PW, Houben AJ, et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 48: 1300-7.
42. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-52.
43. Kistorp C, Chong AY, Gustafsson F, et al. Biomarkers of endothe-lial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart Fail 2008; 10: 380-7.
44. Roldán V, Marín F, García-Herola A, Lip GY. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 2005; 116: 321-5.
45. Lip GY, Blann AD. von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995; 74: 580-3.
46. Jansson J, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
47. Borawski J, Naumnik B, Pawlak K, Mysliwiec M. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001; 16: 1442-7.
48. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-93.
49. Pottinger E, Read RC, Paleolog EG, Higgins PG, Pearson JD. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-94. 73: 1586-91.
50. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with non valvular atrial fibrillation. Circulation 2003; 107: 3141-5.
51. Yanagisawa M, Kurihara H, Kumura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
52. Inoue A, Yanagisawa M, Takuwa Y, Kobayashi M, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Nalt Acad Sci USA 1989; 86: 2863-7.
53. Kishimoto I, Yoshimasa T, Arai H, et al. Endothelin-induced activation of mitogen-activated protein kinases in glomerular mesan-gial cells from normotensive and stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22: 207-8.
54. Schini VB, Vanhoutte PM. Endothelin-1: a potent vasoactive pep-tide. Pharmacol Toxicol 1991; 69: 1-7.
55. Finsnes F, Lyberg T, Christensen G, Skjonsberg OH. Effect of endothelin antagonism on the production of cytokines in eosino-philic airway inflammation. Am J Physiol Lung Cell Mol Physiol 2001, 280: 659-65.
56. McCartney SA, Ballinger AB, Vojnovic I, Farthing MJ, Warner TD. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci 2002; 71: 1893-904.
57. Bohm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endothelium dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci 2002; 102: 321-7.
58. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endo-thelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-44.
59. Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med 1998; 15: 634-42.
60. Blann A, Kumar P, Krupinski J, McCollum C, Beevers DG, Lip GY. Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke. Blood Coagul Fibrinolysis 1999; 10: 277-84.
61. Newman W, Beall LD, Carson CW, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993; 150: 644-54.
62. Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann New York Acad Sci 1992; 667: 324-31.
63. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-4
64. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 814-9.
65. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
66. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101: 363-71.
67. Mitchell CA, Hau L, Salem HH. Control of thrombin mediated cleavage of protein S. Thromb Haemost 1986; 56: 151-4.
68. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochimica et Biophysica Acta 1979; 571: 333-42.
69. Seigneur M, Dufourcq P, Conri C, et al. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993; 12: 355-9
70. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Investig 1985; 76: 2178-81.
71. Iba T, Yagi Y, Kidokoro A, Fukunaga M, Fukunaga T. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surgery Today 1995; 25: 585-90.
72. Tomura S, Nakamura Y, Deguchi F, et al. Plasma von willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990; 58: 413-9.
73. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535-60.
74. Saccani G, Tanzi E, Cavalli S, Rohrer J. Determination of nitrite, nitrate, and glucose-6-phosphate in muscle tissues and cured meat by IC/MS. J AOAC Int 2006; 89: 712-9.
75. Shahar E, Whitney CW, Redline S. Sleep disordered breathing and cardiovascular disease: cross sectional results of sleep heart health study. Am J Respir Crit Care Med 2001; 163: 19-25.
76. Miyazaki H, Matsuoka H, Cooke JP. Endogenous nitric oxide syn-thase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6.
77. Abbasi F, Asagmi T, Cooke JP. Plasma concentrations of asymmetric dimethylarginine are increased in patients with Type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-3.
78. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med 2007; 45: 1683-7.
79. Cooke JP. Asymmetrical dimethylarginine: the über marker? Circulation 2004; 109; 1813-8.
80. Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, Nenseter MS. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr 2003; 89: 359-63.
81. Böger R, Bode-Böger S, Szuba A, et al. Asymetric Dimethylargin-ina (ADMA). A novel risk factor for endothelial Dysfunction. Circulation 1998; 98: 1842-7.
82. Fujiwara N, Osanai T, Kamada T. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101: 856-61.
83. Fard A, Tuck CH, Donis JA. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 2039-44.
84. Holden DP, Fickling SA, Whitley GS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gy-necol 1998; 178: 551-6.
85. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
86. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-32.
87. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 2006; 373: 17-26.
88. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93: 2951-8.
89. Nadar SK, Lip GY, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005; 94: 707-12
90. McClung JA, Naseer N, Saleem M, et al. Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA(1)c. Diabetologia 2005; 48: 345-50.
91. Sinzinger H, Fitscha P, Peskar BA. Platelet half-life, plasma thromboxane B2 and circulating endothelial-cells in peripheral vascular disease. Angiology 1986; 37: 112-8.
92. Dang A, Wang B, Li W, et al. Plasma endothelin-1 levels and circulating endothelial cells in patients with aortoarteritis. Hypertens Res 2000; 23: 541-4.
93. Boos CJ, Soor SK, Kang D, Lip GY. Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes. Eur Heart J 2007; 28: 1092-101.
94. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-508.
95. Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardio-vasc Interv 2007; 70: 477-84.
96. Rafat N, Hanusch C, Brinkkoetter PT, et al. Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med 2007; 35: 1677-84.
97. Valgimigli M, Rigolin GM, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209-12.
98. Kondo T, Hayashi M, Takeshita K, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004; 24: 1442-7.
99. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-6.
100. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
101. Scheubel RJ, Zorn H, Silber RE, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003; 42: 2073-80.
102. Teragawa H, Ueda K, Matsuda K, et al. Relationship between en-dothelial function in the coronary and brachial arteries. Clin Cardiol 2005; 28: 460-6.
103. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic pep-tide. Circulation 2004; 110: 1794-8.
104. Minamino T, Miyauchi H, Yoshida T, Tateno K, Komuro I. The role of vascular cell senescence in atherosclerosis: antisenescence as a novel therapeutic strategy for vascular aging. Curr Vasc Pharmacol 2004; 2: 141-8.
105. Blackwell KA, Sorenson JP, Richardson DM, et al. Mechanisms of aging-induced impairment of endothelium-dependent relaxation: role of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol 2004; 287: H2448-53.
106. Bakker SJ, IJzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endo-thelial dysfunction, and beta-cell failure? Atherosclerosis 2000; 148: 17-21.
107. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95: 2617-22.
108. Njølstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996; 93: 450-6.
109. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149-55.
110. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334: 150-4.
111. Ljungberg LU, Persson K. Effect of nicotine and nicotine metabolites on angiotensin-converting enzyme in human endothelial cells. Endothelium 2008; 15: 239-45.
112. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23.
113. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
114. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 1988; 60: 459-64.
115. Myrup B, Mathiesen ER, Rønn B, Deckert T. Endothelial function and serum lipids in the course of developing microalbuminuria in insulin-dependent diabetes mellitus. Diabetes Res 1994; 26: 33-9.
116. Fasching P, Veitl M, Rohac M, et al. Elevated concentrations of circulating adhesion molecules and their association with mi-crovascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4313-7.
117. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36-52.
118. Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9(6 Pt 2): III193-197.
119. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens 2001; 19: 415-20.
120. Sramek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: re-producibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000; 35: 699-706.
121. Csanyi A, Egervari A. Simple clinical method of average intima-media thickness measurement in the common carotid artery. Vasa 1996; 25: 242-8.
122. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002; 43: 117-25.
123. Hashimoto M, Eto M, Akishita M, Kozaki K, Ako J, Iijima K. Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol 1999; 19: 2795-800.
124. Ramsis N, El Hawary AA, Ismail E. Relation between carotid in-tima-media thickness, platelet surface activation and endothelial cell markers. Haemostasis 1998; 28: 268-75.
125. Millgard J, Hagg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens 1998; 12: 511-6.
126. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002; 40: 61-6.
127. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endo-thelium-derived nitric oxide in the abnormal endothelium dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-74.
128. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of anti-hypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21: 1145-51.
129. Kimura Y, Matsumoto M, Den YB, et al. Impaired endothelial function in hypertensive elderly patients evaluated by high resolution ultrasonography. Can J Cardiol 1999; 15: 563-8
130. Ghiadoni L, Taddei S, Virdis A, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32: 25-32.
131. Lip GY, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8: 693-702.
132. Luscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens - Suppl 1994; 12: S105-16.
133. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4: 51-61.
134. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbrone MA, Jr. Biomechanical activation of vascular endothe-lium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001; 98: 4478-85.
135. Blann AD, Lip GY. Cell adhesion molecules in cardiovascular disease and its risk factors--what can soluble levels tell us? J Clin Endocrinol Metab 2000; 85: 1745-7.
136. Pearson JD. Vessel wall interactions regulating thrombosis. Br Med Bull 1994; 50: 776-88.
137. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17: 187-93.
138. Vallance P, Collier J. Biology and clinical relevance of nitric oxide. BMJ 1994; 309: 453-7.
139. Aigbe A, Famodu AA. Haemorheological and fibrinolytic activity in hypertensive Nigerians. Clin Hemorheol Microcirc 1999; 21: 415-20.
140. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibri-nolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783-8.
141. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcho-line in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33.
142. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endo-thelium dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23: 1610-6.
143. Multiple risk factor intervention trial group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982; 248: 1465-77.
144. Agewall S, Hernberg A. Atorvastatin normalizes endothelial function in healthy smokers. Clin Sci 2006; 111: 87-91.
145. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31
146. Kassan M, Montero MJ, Sevilla MA. In vitro antioxidant activity of pravastatin provides vascular protection. Eur J Pharmacol 2010; 630: 107-11.
147. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
148. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.
149. Boos CJ, Balakrishnan B, Blann AD, Lip GY. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008; 6: 1841-50.
150. Lip GY, Blann AD, Edmunds E, Beevers DG. Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul Fibrinol 2002; 13: 35-41.
151. Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Wille-brand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007; 261: 384-91.
152. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005; 1: 183-98.
153. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
154. Dupuis J, Tardif JC, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.
155. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
156. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
157. The 4S investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sim-vastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
158. Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Car-diol 1997; 80: 1566-71.
159. Lip GY, Edmunds E, Hee FL, Blann AD, Beevers DG. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 2001; 14: 823-8.
160. Sibal L, Agarwal SC, Schwedhelm E, Lüneburg N, Böger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol 2009; 8: 27.
161. Meyer MF, Lieps D, Schatz H, Pfohl M. Impaired flow-mediated vasodilation in type 2 diabetes: lack of relation to microvascular dysfunction. Microvasc Res 2008; 76: 61-5.
162. Maas R, Schwedhelm E, Kahl L, et al. Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem 2008; 54: 292-300.
163. Hamburg NM, Charbonneau F, Gerhard-Herman M, Ganz P, Crea-ger MA. Comparison of endothelial function in young men and women with a family history of premature coronary artery disease. Am J Cardiol 2004; 94: 783-5.
164. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmeno-pausal women. J Am Coll Cardiol 2002; 40: 505-10.
165. Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of non-invasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-75.
166. DeSouza CA, Shapiro LF, Clevenger CM, et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000; 102: 1351-7.
167. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-9.
168. Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO 3rd. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol 1997; 30: 1220-7.
169. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-20.
170. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-54.
171. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-50.
172. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-90.
173. Ghiadoni L, Versari D, Giannarelli C, Faita F, Taddei S. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des 2008; 14(35): 3715-22.
174. Santarelli MF, Landini L, Positano V, Landini L. Can Imaging Techniques identify smoking-related cardiovascular disease? Curr Pharm Des 2010; 16(23): 2578-85.
175. Virdis A, Ghiadoni L, Versari D, Giannarelli C, Salvetti A, Taddei S. Endothelial function assessment in complicated hypertension. Curr Pharm Des 2008; 14(18): 1761-70.